A Phase 2 interventional study of secukinumab 300 mg Q4W and secukinumab 300 mg Q2W in Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris, sponsored by Novartis Pharmaceuticals. Completed at 35 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Lichen Planus with a site in United States — 6 open to participants now, 7 under way, 1 of them phase 3. Lichen Planus · United States.
Among the 33 studies in Lichen Planus with a site in United States, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2020, is one of 17 in phase 2, and was the 18th registered.
75 studies on the registry are indexed under Lichen Planus; 16 are open to participants now.
Browse Lichen Planus studies →6 of the 33 studies in Lichen Planus with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 1 more country
Ages 18–99
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Priovant Therapeutics, Inc. · Sites in United States, Australia, Canada and 1 more country
Ages 18+
The Skin Center Dermatology Group · Sites in United States
Ages 18+
Henry Ford Health System · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Lichen Planus studies recruiting now, 6 (50%) set no upper age limit and 3 (25%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 18 · Phase 3 1 · Phase 4 2
First in 1996; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 30 across 56 interventional studies indexed under Lichen Planus.
Median enrollment 20 across the 26 interventional studies, 80 across the 7 observational. Of the 23 that completed or were terminated, 12 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 2 studies filed under Lichen Planus — fewer than ten, so there is no comparison to draw.
4 of the studies in Lichen Planus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07487948Icahn School of Medicine at Mount SinaiSafety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris | 2027-04-05 |
| NCT00542373M.D. Anderson Cancer CenterWidefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer | 2027-04-30 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
| NCT07396168The Skin Center Dermatology GroupNemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study. | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 33 studies in Lichen Planus with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of the proof of concept study is to elucidate the efficacy of secukinumab in the treatment of adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies, and to assess the safety and tolerability over 32 weeks.
This was a 32-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial which assessed the efficacy and safety of secukinumab 300 mg in two different dosing regimens: every 4 weeks (Q4W) and every 2 weeks (Q2W) in approximately 111 patients with biopsy-proven forms of lichen planus.
There was a screening period (up to 4 weeks prior to baseline), a treatment period 1 (baseline to Week 16), a treatment period 2 (Week 16 to Week 32) and a follow-up period (8 weeks after Week 32).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have -confirmed forms of cutaneous lichen planus (CLP), mucosal lichen planus (MLP), or active lichen planopilaris (LPP) eligible for systemic therapy based on the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab 300 mg every 4 weeks provided in pre-filled syringe in cutaneous lichen planus patients
Drug: secukinumab 300 mg Q4W
Placebo in 1ml PFS in cutaneous lichen patients
Other: Placebo
Secukinumab 300 mg every 4 weeks provided in pre-filled syringe in mucosal lichen planus patients.
Drug: secukinumab 300 mg Q4W
Placebo 1 ml PFS in mucosal lichen planus patients
Other: Placebo
Secukinumab 300 mg every 4weeks provided in pre-filled syringe in lichen planopilaris patients.
Drug: secukinumab 300 mg Q4W
Placebo in 1ml PFS in lichen planopilaris patients
Other: Placebo
Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2
Drug: secukinumab 300 mg Q2W
Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2
Drug: secukinumab 300 mg Q2W
Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2
Drug: secukinumab 300 mg Q2W
secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.
Also known as: AIN457
secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.
Also known as: AIN457
Matching placebo administered via a pre-filled syringe
Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP
Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model.
Time frame: Baseline up to week 16
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)
Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)
The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=\<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=\>50% of total body surface
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)
The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".
Time frame: Baseline, Week 16 and Week 32
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)
Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".
Time frame: Baseline, Week 16 and Week 32
Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".
Time frame: Baseline, Week 16 and Week 32
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)
Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".
Time frame: Baseline, Week 16 and Week 32
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)
Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".
Time frame: Baseline, Week 16 and Week 32
Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)
Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".
Time frame: Baseline, Week 16 and Week 32
Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period
REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease.
Time frame: Baseline, Week 16 and Week 32
Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period
OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity.
Time frame: Baseline, Week 16 and Week 32
Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)
The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity
Time frame: Baseline, Week 16 and Week 32
Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)
Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life.
Time frame: Baseline, Week 16 and Week 32
| Milestone | AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - CLP Cohort | AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - MLP Cohort | AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - LPP Cohort |
|---|---|---|---|---|---|---|
| Started | 25 | 12 | 24 | 13 | 24 | 13 |
| Placebo responder | 0 | 1 | 0 | 1 | 0 | 0 |
| Completed | 23 | 10 | 24 | 13 | 23 | 12 |
| Not completed | 2 | 2 | 0 | 0 | 1 | 1 |
| Withdrew: Progressive disease | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Subject/guardian decision | 1 | 2 | 0 | 0 | 0 | 1 |
| Milestone | AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - CLP Cohort | AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - MLP Cohort | AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | Placebo in TP1 to AIN457 300 mg Q2W - TP 2 - LPP Cohort |
|---|---|---|---|---|---|---|
| Started | 22 | 8 | 23 | 11 | 23 | 12 |
| Completed | 17 | 7 | 19 | 10 | 17 | 12 |
| Not completed | 5 | 1 | 4 | 1 | 6 | 0 |
| Withdrew: Adverse event | 1 | 0 | 2 | 0 | 1 | 0 |
| Withdrew: Progressive disease | 2 | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Subject/guardian decision | 2 | 0 | 1 | 1 | 3 | 0 |
Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model.
| percentage of participants | AIN457 300 mg Q4W - TP 1 - CLP Cohort | Placebo - TP 1 - CLP Cohort | AIN457 300 mg Q4W - TP 1 - MLP Cohort | Placebo - TP 1 - MLP Cohort | AIN457 300 mg Q4W - TP 1 - LPP Cohort | Placebo - TP 1 - LPP Cohort |
|---|---|---|---|---|---|---|
| Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP | 44.0 (25.8 to 63.32) | 58.2 (31.0 to 82.6) | 37.5 (20.3 to 57.2) | 23.1 (6.5 to 49.2) | 37.6 (20.2 to 57.3) | 30.9 (10.8 to 57.6) |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.
| Participants | AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | Placebo - TP 1 - CLP Cohort | Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort |
|---|---|---|---|
| Week 2 IGA <=2 n=25,12,0 | 5 | 1 | — |
| Week 2 IGA improvement >=2 n=25,12,0 | 2 | 0 | — |
| Week 2 IGA 0/1 n=25,12,0 | 2 | 0 | — |
| Week 4 IGA <=2 n=24,11,0 | 9 | 2 | — |
| Week 4 IGA improvement. >=2 n=24,11,0 | 3 | 0 | — |
| Week 4 IGA 0/1 n=24,11,0 | 2 | 0 | — |
| Week 8 IGA <=2 n=25,11,0 | 10 | 3 | — |
| Week 8 IGA improvement. >=2 n=25,11,0 | 4 | 1 | — |
| Week 8 IGA 0/1 n=25,11,0 | 3 | 1 | — |
| Week 12 IGA <=2 n=25,12,0 | 10 | 4 | — |
| Week 12 IGA improvement. >=2 n=25,12,0 | 3 | 2 | — |
| Week 12 IGA 0/1 n=25,12,0 | 4 | 1 | — |
| Week16 IGA <=2 n=25,12,10 | 11 | 7 | 5 |
| Week 16 IGA improvement. >=2 n=25,12,10 | 4 | 3 | 1 |
| Week 16 IGA 0/1 n=25,12,10 | 4 | 2 | 0 |
| Week 20 IGA <=2 n=24,0,10 | 11 | — | 1 |
| Week 20 IGA improvement. >=2 n=24,0,10 | 5 | — | 1 |
| Week 20 IGA 0/1 n=24,0,10 | 5 | — | 1 |
| Week 24 IGA <=2 n=25,0,10 | 14 | — | 3 |
| Week 24 IGA improvement. >=2 n=25,0,10 | 10 | — | 2 |
| Week 24 IGA 0/1 n=25,0,10 | 10 | — | 1 |
| Week 28 IGA <=2 n=23,0,10 | 12 | — | 4 |
| Week 28 IGA improvement. >=2 n=23,0,10 | 7 | — | 1 |
| Week 28 IGA 0/1 n=23,0,10 | 6 | — | 1 |
| Week 32 IGA <=2 n=24,0,9 | 9 | — | 2 |
| Week 32 IGA improvement. >=2 n=24,0,9 | 7 | — | 2 |
| Week 32 IGA 0/1 n=24,0,9 | 6 | — | 1 |
Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.
| Participants | AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | Placebo - TP 1 - MLP Cohort | Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort |
|---|---|---|---|
| Week 2 IGA <=2 n=24,12,0 | 5 | 3 | — |
| Week 2 IGA improvement >=2 n=24,12,0 | 1 | 1 | — |
| Week 2 IGA 0/1 n=24,12,0 | 1 | 1 | — |
| Week 4 IGA <=2 n=24,13,0 | 4 | 2 | — |
| Week 4 IGA improvement. >=2 n=24,13,0 | 1 | 1 | — |
| Week 4 IGA 0/1 n=24,13,0 | 1 | 1 | — |
| Week 8 IGA <=2 n=24,13,0 | 5 | 3 | — |
| Week 8 IGA improvement. >=2 n=24,13,0 | 0 | 2 | — |
| Week 8 IGA 0/1 n=24,13,0 | 0 | 1 | — |
| Week 12 IGA <=2 n=24,13,0 | 5 | 4 | — |
| Week 12 IGA improvement. >=2 n=24,13,0 | 5 | 4 | — |
| Week 12 IGA 0/1 n=24,13,0 | 4 | 2 | — |
| Week16 IGA <=2 n=24,13,11 | 9 | 3 | 1 |
| Week 16 IGA improvement. >=2 n=24,13,11 | 5 | 3 | 1 |
| Week 16 IGA 0/1 n=24,13,11 | 4 | 2 | 0 |
| Week 20 IGA <=2 n=24,0,11 | 10 | — | 3 |
| Week 20 IGA improvement. >=2 n=24,0,11 | 5 | — | 2 |
| Week 20 IGA 0/1 n=24,0,11 | 5 | — | 1 |
| Week 24 IGA <=2 n=24,0,10 | 10 | — | 4 |
| Week 24 IGA improvement. >=2 n=24,0,10 | 3 | — | 2 |
| Week 24 IGA 0/1 n=24,0,10 | 3 | — | 0 |
| Week 28 IGA <=2 n=23,0,11 | 7 | — | 4 |
| Week 28 IGA improvement. >=2 n=23,0,11 | 1 | — | 3 |
| Week 28 IGA 0/1 n=23,0,11 | 1 | — | 0 |
| Week 32 IGA <=2 n=23,0,10 | 9 | — | 2 |
| Week 32 IGA improvement. >=2 n=23,0,10 | 2 | — | 1 |
| Week 32 IGA 0/1 n=23,0,10 | 2 | — | 0 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score.
| Participants | AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | Placebo - TP 1 - LPP Cohort | Placebo to AIN457 300 mg Q2W - TP 2- LPP Cohort |
|---|---|---|---|
| Week 2 IGA <=2 n=24,13,0 | 4 | 1 | — |
| Week 2 IGA improvement >=2 n=24,13,0 | 1 | 0 | — |
| Week 2 IGA 0/1 n=24,13,0 | 1 | 0 | — |
| Week 4 IGA <=2 n=24,13,0 | 9 | 2 | — |
| Week 4 IGA improvement. >=2 n=24,13,0 | 2 | 1 | — |
| Week 4 IGA 0/1 n=24,13,0 | 2 | 1 | — |
| Week 8 IGA <=2 n=24,13,0 | 8 | 3 | — |
| Week 8 IGA improvement. >=2 n=24,13,0 | 3 | 1 | — |
| Week 8 IGA 0/1 n=24,13,0 | 3 | 1 | — |
| Week 12 IGA <=2 n=24,13,0 | 8 | 4 | — |
| Week 12 IGA improvement. >=2 n=24,13,0 | 3 | 2 | — |
| Week 12 IGA 0/1 n=24,13,0 | 2 | 2 | — |
| Week16 IGA <=2 n=24,13,13 | 9 | 4 | 4 |
| Week 16 IGA improvement. >=2 n=24,13,13 | 3 | 0 | 0 |
| Week 16 IGA 0/1 n=24,13,13 | 2 | 0 | 0 |
| Week 20 IGA <=2 n=24,0,13 | 10 | — | 6 |
| Week 20 IGA improvement. >=2 n=24,0,13 | 6 | — | 1 |
| Week 20 IGA 0/1 n=24,0,13 | 4 | — | 0 |
| Week 24 IGA <=2 n=23,0,13 | 10 | — | 8 |
| Week 24 IGA improvement. >=2 n=23,0,13 | 7 | — | 3 |
| Week 24 IGA 0/1 n=23,0,13 | 6 | — | 2 |
| Week 28 IGA <=2 n=24,0,13 | 10 | — | 9 |
| Week 28 IGA improvement. >=2 n=24,0,13 | 6 | — | 4 |
| Week 28 IGA 0/1 n=24,0,13 | 5 | — | 3 |
| Week 32 IGA <=2 n==24,0,11 | 11 | — | 7 |
| Week 32 IGA improvement. >=2 n==24,0,11 | 5 | — | 5 |
| Week 32 IGA 0/1 n==24,0,11 | 4 | — | 4 |
The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=\<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=\>50% of total body surface
| Participants | AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | Placebo - TP 1 - CLP Cohort | Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort |
|---|---|---|---|
| Baseline 0 Score | 0 | 0 | — |
| Baseline 1 score | 3 | 0 | — |
| Baseline 2 score | 6 | 0 | — |
| Baseline 3 score | 6 | 3 | — |
| Baseline 4 score | 5 | 6 | — |
| Baseline 5 score | 5 | 3 | — |
| Week 2 0 score | 0 | 0 | 0 |
| Week 2 1 score | 6 | 0 | — |
| Week 2 2 score | 5 | 1 | — |
| Week 2 3 score | 9 | 3 | — |
| Week 2 4 score | 3 | 5 | — |
| Week 2 5 score | 2 | 3 | — |
| Week 4 0 score | 0 | 0 | — |
| Week 4 1 score | 3 | 0 | — |
| Week 4 2 score | 8 | 0 | — |
| Week 4 3 score | 8 | 3 | — |
| Week 4 4 score | 3 | 5 | — |
| Week 4 5 score | 2 | 3 | — |
| Week 8 0 score | 0 | 0 | — |
| Week 8 1 score | 7 | 1 | — |
| Week 8 2 score | 5 | 1 | — |
| Week 8 3 score | 7 | 2 | — |
| Week 8 4 score | 4 | 4 | — |
| Week 8 5 score | 2 | 3 | — |
| Week 12 0 score | 0 | 0 | — |
| Week 12 1 score | 6 | 1 | — |
| Week 12 2 score | 7 | 2 | — |
| Week 12 3 score | 7 | 0 | — |
| Week 12 4 score | 3 | 7 | — |
| Week 12 5 score | 2 | 2 | — |
| Week 16 0 score | 0 | 0 | 0 |
| Week 16 1 score | 4 | 2 | 0 |
| Week 16 2 score | 12 | 3 | 3 |
| Week 16 3 score | 5 | 3 | 3 |
| Week 16 4 score | 2 | 4 | 4 |
| Week 16 5 score | 2 | 0 | 0 |
| Week 20 0 score | 0 | — | 0 |
| Week 20 1 score | 6 | — | 0 |
| Week 20 2 score | 12 | — | 3 |
| Week 20 3 score | 3 | — | 2 |
| Week 20 4 score | 1 | — | 3 |
| Week 20 5 score | 2 | — | 2 |
| Week 24 0 score | 1 | — | 0 |
| Week 24 1 score | 8 | — | 0 |
| Week 24 2 score | 10 | — | 2 |
| Week 24 3 score | 1 | — | 2 |
| Week 24 4 score | 2 | — | 4 |
| Week 24 5 score | 3 | — | 2 |
| Week 28 0 score | 0 | — | 0 |
| Week 28 1 score | 6 | — | 0 |
| Week 28 2 score | 11 | — | 2 |
| Week 28 3 score | 1 | — | 3 |
| Week 28 4 score | 3 | — | 3 |
| Week 28 5 score | 2 | — | 2 |
| Week 32 0 score | 2 | — | 0 |
| Week 32 1 score | 5 | — | 1 |
| Week 32 2 score | 10 | — | 0 |
| Week 32 3 score | 3 | — | 4 |
| Week 32 4 score | 1 | — | 2 |
| Week 32 5 score | 3 | — | 2 |
The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.
| Participants | AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | Placebo - TP 1 - CLP Cohort | Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort |
|---|---|---|---|
| Baseline n=25,12,0 | 0 | 0 | — |
| Week 4 n=24,11,0 | 2 | 0 | — |
| Week 8 n=25,11,0 | 2 | 0 | — |
| Week 12 n=25,12,0 | 3 | 1 | — |
| Week 16 n=25,12,10 | 3 | 2 | 2 |
| Week 20 n=24,0,10 | 3 | — | 1 |
| Week 24 n=25,0,10 | 4 | — | 1 |
| Week 28 n=23,0,10 | 3 | — | 1 |
| Week 32 n=25,0,9 | 2 | — | 1 |
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.
| Participants | AIN457 300 mg Q4W - TP 1 and TP 2- MLP Cohort | Placebo - TP 1 - MLP Cohort | Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort |
|---|---|---|---|
| Baseline n=24,13,0 | 0 | 0 | — |
| Week 4 n=24,13,0 | 2 | 1 | — |
| Week 8 n=24,13,0 | 4 | 1 | — |
| Week 12 n=24,13,0 | 4 | 2 | — |
| Week 16 n=24,13,11 | 5 | 3 | 2 |
| Week 20 n=24,0,11 | 7 | — | 2 |
| Week 24 n=24,0,10 | 7 | — | 3 |
| Week 28 n=23,0,11 | 3 | — | 2 |
| Week 32 n=23,0,10 | 4 | — | 2 |
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.
| Participants | AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | Placebo - TP 1 - LPP Cohort | Placebo to AIN457 300 mg Q2W TP 2 - LPP Cohort |
|---|---|---|---|
| Baseline n=24,13,0 | 0 | 0 | — |
| Week 4 n=24,13,0 | 3 | 1 | — |
| Week 8 n=24,13,0 | 3 | 1 | — |
| Week 12 n=24,13,0 | 2 | 2 | — |
| Week 16 n=24,13,13 | 2 | 1 | 1 |
| Week 20 n=24,0,13 | 4 | — | 3 |
| Week 24 n=23,0,13 | 2 | — | 3 |
| Week 28 n=24,0,13 | 2 | — | 2 |
| Week 32 n=24,0,11 | 1 | — | 3 |
Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".
| scores on a scale | AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | Placebo - TP 1 - CLP Cohort | Placebo to AIN457 300 mg Q2W TP 2 - CLP Cohort |
|---|---|---|---|
| Baseline - Question 1 | 5.1 ± 2.66 | 5.7 ± 2.77 | 5.8 ± 3.01 |
| Week 16 Severity of itch during past 24 hours n=25,12,10 | -0.8 ± 1.91 | -2.3 ± 3.25 | -2.0 ± 3.53 |
| Week 32 Severity of itch during past 24 hours n=25,0,9 | -1.5 ± 2.24 | — | -1.1 ± 2.42 |
| Baseline- Question 2 | 5.6 ± 2.72 | 6.3 ± 2.86 | 5.9 ± 3.03 |
| Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10 | -0.9 ± 2.52 | -2.7 ± 3.73 | -1.9 ± 3.54 |
| Week 32 How severe was itch at worst moment during past 24 hours n=25,0,9 | -1.3 ± 2.13 | — | -1.2 ± 2.49 |
| Baseline- Question 3 | 4.8 ± 3.08 | 6.1 ± 2.94 | 6.1 ± 3.21 |
| Week 16 How bothered by Itch during past 24 hours n=25,12,10 | -1.0 ± 2.65 | -2.7 ± 3.55 | -2.4 ± 3.84 |
| Week 32 How bothered by Itch during past 24 hours n=25,0,9 | -1.1 ± 2.45 | — | -1.2 ± 2.28 |
Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".
| scores on a scale | AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | Placebo - TP 1 - MLP Cohort | Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort |
|---|---|---|---|
| Baseline - Question 1 n=23,13,11 | 2.5 ± 2.83 | 3.8 ± 3.81 | 4.3 ± 3.93 |
| Week 16 Severity of itch during past 24 hours n=23,13,11 | 0.3 ± 3.26 | -0.2 ± 3.41 | -0.3 ± 3.72 |
| Week 32 Severity of itch during past 24 hours n=22,0,10 | 0.1 ± 2.97 | — | -0.4 ± 3.37 |
| Baseline - Question 2 n=23,13,11 | 2.4 ± 2.90 | 3.6 ± 3.99 | 4.1 ± 4.16 |
| Week 16 How severe was itch at worst moment during past 24 hours n=23,13,11 | 0.8 ± 3.04 | 0.4 ± 3.25 | 0.4 ± 3.56 |
| Week 32 How severe was itch at worst moment during past 24 hours n=22,0,10 | 0.3 ± 2.43 | — | 0.4 ± 3.81 |
| Baseline - Question 3 n=24,13,11 | 3.4 ± 3.41 | 4.0 ± 4.14 | 4.5 ± 4.27 |
| Week 16 How bothered by Itch during past 24 hours n=23,13,11 | -0.5 ± 2.95 | 0.1 ± 3.12 | 0.0 ± 3.41 |
| Week 32 How bothered by Itch during past 24 hours n=22,0,10 | -0.2 ± 1.33 | — | -0.4 ± 4.25 |
Itch is assessed with the following questions: • "Overall, how severe was your lichen planus-related itching during the past 24 hours?" • "How severe was your lichen planus-related itching at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related itching during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no itch" and 10 meaning "the worst itch imaginable".
| scores on a scale | AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | Placebo - TP 1 - LPP Cohort | Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort |
|---|---|---|---|
| Baseline - Question 1 n=24,13,13 | 4.5 ± 2.25 | 3.8 ± 2.68 | 3.8 ± 2.68 |
| Week 16 Severity of itch during past 24 hours n=24,13,11 | -0.5 ± 2.25 | -1.1 ± 2.47 | -1.1 ± 2.47 |
| Week 32 Severity of itch during past 24 hours n=24,0,11 | -1.6 ± 2.06 | — | -2.4 ± 2.84 |
| Baseline - Question 2 n=24,13,13 | 5.1 ± 2.43 | 4.2 ± 2.86 | 4.1 ± 4.16 |
| Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13 | -0.7 ± 2.35 | -1.3 ± 2.81 | -1.3 ± 2.81 |
| Week 32 How severe was itch at worst moment during past 24 hours n=24,0,11 | -1.8 ± 2.23 | — | -2.6 ± 3.01 |
| Baseline - Question 3 n=24,13,11 | 4.0 ± 2.36 | 3.2 ± 2.79 | 3.2 ± 2.79 |
| Week 16 How bothered by Itch during past 24 hours n=24,13,13 | -0.4 ± 2.43 | -1.2 ± 3.02 | -1.2 ± 3.02 |
| Week 32 How bothered by Itch during past 24 hours n=24,0,11 | -1.7 ± 2.08 | — | -2.2 ± 2.44 |
Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".
| scores on a scale | AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | Placebo - TP 1 - CLP Cohort | Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort |
|---|---|---|---|
| Baseline - Question 1 n=25,12,10 | 1.09 ± 2.05 | 3.4 ± 2.61 | 3.5 ± 2.51 |
| Week 16 Severity of pain during past 24 hours n=25,12,10 | 0.2 ± 1.48 | -0.8 ± 1.40 | -0.8 ± 1.48 |
| Week 32 Severity of pain during past 24 hours n=25,0,9 | -0.3 ± 1.65 | — | -0.3 ± 2.29 |
| Baseline - Question 2 n=25,12,10 | 2.2 ± 2.48 | 3.9 ± 3.23 | 3.9 ± 3.03 |
| Week 16 How severe was pain at worst moment during past 24 hours n=25,12,10 | 0.1 ± 2.03 | -1.2 ± 1.70 | -1.0 ± 1.56 |
| Week 32 How severe was pain at worst moment during past 24 hours n=25,0,9 | -0.4 ± 2.35 | — | -0.4 ± 2.70 |
| Baseline - Question 3 n=25,12,10 | 2.1 ± 2.55 | 3.7 ± 2.96 | 3.8 ± 2.94 |
| Week 16 How bothered by pain during past 24 hour n=25,12,10 | 0.1 ± 2.09 | -0.6 ± 1.62 | 0.5 ± 1.72 |
| Week 32 How bothered by pain during past 24 hours n=25, 0,9 | -0.2 ± 1.71 | — | -0.3 ± 2.45 |
Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".
| scores on a scale | AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | Placebo - TP 1 - MLP Cohort | Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort |
|---|---|---|---|
| Baseline - Question 1 n=24,13,11 | 5.1 ± 2.86 | 5.9 ± 3.09 | 6.3 ± 3.23 |
| Week 16 Severity of pain during past 24 hours n=24,13,11 | -0.5 ± 3.08 | -0.1 ± 3.01 | 0.0 ± 3.29 |
| Week 32 Severity of pain during past 24 hours n=23,0,10 | -0.3 ± 2.18 | — | -0.6 ± 2.59 |
| Baseline - Question 2 n=24,13,11 | 5.4 ± 2.99 | 6.4 ± 3.15 | 6.7 ± 3.26 |
| Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11 | -0.5 ± 3.13 | -0.3 ± 2.75 | -0.2 ± 2.99 |
| Week 32 How severe was pain at worst moment during past 24 hours n=23,0,10 | -0.3 ± 2.06 | — | -0.5 ± 2.46 |
| Baseline - Question 3 n=24,13,11 | 5.5 ± 3.35 | 6.5 ± 2.76 | 6.8 ± 2.79 |
| Week 16 How bothered by pain during past 24 hour n=24,13,11 | -0.8 ± 3.54 | -0.3 ± 2.21 | -0.1 ± 2.34 |
| Week 32 How bothered by pain during past 24 hours n=23,0,10 | -0.5 ± 2.74 | — | -0.9 ± 2.69 |
Pain is assessed with the following questions: • "Overall, how severe was your lichen planus-related pain during the past 24 hours?" • "How severe was your lichen planus-related pain at the worst moment during the past 24 hours?" • "Overall, how bothered were you by your lichen planus-related pain during the past 24 hours?" Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning "no pain" and 10 meaning "the worst pain imaginable".
| scores on a scale | AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | Placebo - TP 1 - LPP Cohort | Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort |
|---|---|---|---|
| Baseline - Question 1 n=24,13,12 | 2.5 ± 2.43 | 2.0 ± 2.38 | 2.0 ± 2.38 |
| Week 16 Severity of pain during past 24 hours n=24,13,12 | 0.3 ± 2.61 | -0.5 ± 1.90 | -0.5 ± 1.90 |
| Week 32 Severity of pain during past 24 hours n=24,0,11 | -0.6 ± 1.72 | — | -1.5 ± 2.02 |
| Baseline - Question 2 24,13,12 | 2.8 ± 2.68 | 2.5 ± 2.73 | 2.5 ± 2.73 |
| Week 16 How severe was pain at worst moment during past 24 hours n=24,13,12 | 0.2 ± 3.16 | -0.9 ± 2.25 | -0.9 ± 2.25 |
| Week 32 How severe was pain at worst moment during past 24 hours n=24,0,11 | -0.8 ± 2.06 | — | -2.0 ± 2.45 |
| Baseline - Question 3 n=24,13,12 | 2.7 ± 2.56 | 2.4 ± 2.75 | 2.4 ± 2.75 |
| Week 16 How bothered by pain during past 24 hour n=24,13,12 | 0.0 ± 2.87 | -1.1 ± 2.25 | -1.1 ± 2.25 |
| Week 32 How bothered by pain during past 24 hours n=24,0,11 | -0.8 ± 1.79 | — | -1.9 ± 2.51 |
REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease.
| scores on a scale | AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | Placebo - TP 1 - MLP Cohort | Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort |
|---|---|---|---|
| Baseline n=21,12,10 | 21.31 ± 8.747 | 25.29 ± 9.102 | 26.95 ± 8.855 |
| Week 16 n=21,12,10 | -4.83 ± 11.102 | -5.79 ± 14.476 | -4.10 ± 15.196 |
| Week 32 n=20,0,9 | -6.08 ± 10.206 | — | -2.17 ± 15.802 |
OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity.
| scores on a scale | AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | Placebo - TP 1 - MLP Cohort | Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort |
|---|---|---|---|
| Baseline n=21,12,10 | 11.0 ± 5.98 | 13.4 ± 5.50 | 13.9 ± 5.78 |
| Week 16 n=21,12,10 | -1.0 ± 6.82 | 0.8 ± 6.47 | -0.4 ± 7.09 |
| Week 32 n=20,0,9 | -1.8 ± 5.67 | — | -0.7 ± 7.00 |
The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity
| scores on a scale | AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | Placebo - TP 1 - LPP Cohort | Placebo to AIN457 300 mg Q2W TP 2 - Lpp Cohort |
|---|---|---|---|
| Baseline n=24,13,13 | 5.92 ± 2.071 | 5.95 ± 1.767 | 5.95 ± 1.767 |
| Week 16 n=24,13,13 | -1.44 ± 2.517 | -2.24 ± 2.522 | -2.24 ± 2.522 |
| Week 32 n=24,0,13 | -2.44 ± 2.428 | — | -3.20 ± 2.927 |
Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life.
| scores on a scale | AIN457 300 mg Q4W - TP 1 and TP 2 -LPP Cohort | Placebo - TP 1 - LPP Cohort | Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort |
|---|---|---|---|
| Baseline n=24,13,12 | 55.75 ± 16.476 | 54.01 ± 23.252 | 54.01 ± 23.252 |
| Week 16 n=24,13,12 | 1.86 ± 10.695 | -6.94 ± 11.508 | -6.94 ± 11.508 |
| Week 32 n=24,0,11 | -4.26 ± 12.876 | — | -14.43 ± 16.464 |
Collected over Adverse events were reported from first dose of study treatment up to a maximum of 300 days which included an approximate follow up period of 8 weeks for AIN457 treatment groups.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 300 mg Q4W - CLP Cohort | 0/25 (0%) | 0/25 (0%) | 15/25 (60%) |
| Placebo - CLP Cohort | 0/12 (0%) | 1/12 (8.3%) | 7/12 (58.3%) |
| Any AIN457 300 mg - CLP Cohort | 0/33 (0%) | 0/33 (0%) | 21/33 (63.6%) |
| Placebo to AIN457 300 mg Q2W - CLP Cohort | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| AIN457 300 mg Q4W - MLP Cohort | 0/24 (0%) | 1/24 (4.2%) | 18/24 (75%) |
| Placebo - MLP Cohort | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Any AIN457 300 mg - MLP Cohort | 0/35 (0%) | 2/35 (5.7%) | 26/35 (74.3%) |
| Placebo to AIN457 300 mg Q2W - MLP Cohort | 0/11 (0%) | 1/11 (9.1%) | 8/11 (72.7%) |
| AIN457 300 mg Q4W - LPP Cohort | 0/24 (0%) | 0/24 (0%) | 16/24 (66.7%) |
| Placebo - LPP Cohort | 0/13 (0%) | 1/13 (7.7%) | 7/13 (53.8%) |
| Any AIN457 300 mg - LPP Cohort | 0/36 (0%) | 1/36 (2.8%) | 22/36 (61.1%) |
| Placebo to AIN457 300 mg Q2W - LPP Cohort | 0/12 (0%) | 1/12 (8.3%) | 6/12 (50%) |
| Event | AIN457 300 mg Q4W - CLP Cohort | Placebo - CLP Cohort | Any AIN457 300 mg - CLP Cohort | Placebo to AIN457 300 mg Q2W - CLP Cohort | AIN457 300 mg Q4W - MLP Cohort | Placebo - MLP Cohort | Any AIN457 300 mg - MLP Cohort | Placebo to AIN457 300 mg Q2W - MLP Cohort | AIN457 300 mg Q4W - LPP Cohort | Placebo - LPP Cohort | Any AIN457 300 mg - LPP Cohort | Placebo to AIN457 300 mg Q2W - LPP Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/25 | 0/12 | 0/33 | 0/8 | 0/24 | 0/13 | 1/35 | 1/11 | 0/24 | 0/13 | 0/36 | 0/12 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 1/12 | 0/33 | 0/8 | 0/24 | 0/13 | 0/35 | 0/11 | 0/24 | 0/13 | 0/36 | 0/12 |
| NeuralgiaNervous system disorders | 0/25 | 0/12 | 0/33 | 0/8 | 0/24 | 0/13 | 0/35 | 0/11 | 0/24 | 0/13 | 1/36 | 1/12 |
| Angina pectorisCardiac disorders | 0/25 | 0/12 | 0/33 | 0/8 | 0/24 | 0/13 | 0/35 | 0/11 | 0/24 | 1/13 | 0/36 | 0/12 |
| Colitis ulcerativeGastrointestinal disorders | 0/25 | 0/12 | 0/33 | 0/8 | 1/24 | 0/13 | 1/35 | 0/11 | 0/24 | 0/13 | 0/36 | 0/12 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 0/25 | 0/12 | 0/33 | 0/8 | 1/24 | 0/13 | 1/35 | 0/11 | 0/24 | 0/13 | 0/36 | 0/12 |
| Event | AIN457 300 mg Q4W - CLP Cohort | Placebo - CLP Cohort | Any AIN457 300 mg - CLP Cohort | Placebo to AIN457 300 mg Q2W - CLP Cohort | AIN457 300 mg Q4W - MLP Cohort | Placebo - MLP Cohort | Any AIN457 300 mg - MLP Cohort | Placebo to AIN457 300 mg Q2W - MLP Cohort | AIN457 300 mg Q4W - LPP Cohort | Placebo - LPP Cohort | Any AIN457 300 mg - LPP Cohort | Placebo to AIN457 300 mg Q2W - LPP Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/25 | 0/12 | 3/33 | 0/8 | 0/24 | 1/13 | 2/35 | 2/11 | 5/24 | 2/13 | 5/36 | 0/12 |
| Abdominal painGastrointestinal disorders | 0/25 | 0/12 | 0/33 | 0/8 | 0/24 | 1/13 | 2/35 | 2/11 | 0/24 | 0/13 | 0/36 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 2/25 | 0/12 | 3/33 | 1/8 | 1/24 | 0/13 | 3/35 | 2/11 | 0/24 | 0/13 | 0/36 | 0/12 |
| COVID-19Infections and infestations | 1/25 | 0/12 | 2/33 | 1/8 | 2/24 | 0/13 | 4/35 | 2/11 | 0/24 | 1/13 | 0/36 | 0/12 |
| Lichen planusSkin and subcutaneous tissue disorders | 3/25 | 1/12 | 4/33 | 1/8 | 4/24 | 0/13 | 5/35 | 1/11 | 1/24 | 0/13 | 2/36 | 1/12 |
| HypertensionVascular disorders | 2/25 | 0/12 | 2/33 | 0/8 | 1/24 | 1/13 | 1/35 | 0/11 | 1/24 | 2/13 | 2/36 | 1/12 |
| AstheniaGeneral disorders | 0/25 | 1/12 | 1/33 | 1/8 | 0/24 | 0/13 | 0/35 | 0/11 | 1/24 | 0/13 | 1/36 | 0/12 |
| Fungal skin infectionInfections and infestations | 0/25 | 0/12 | 1/33 | 1/8 | 0/24 | 0/13 | 0/35 | 0/11 | 0/24 | 0/13 | 0/36 | 0/12 |
| Post-acute COVID-19 syndromeInfections and infestations | 0/25 | 0/12 | 1/33 | 1/8 | 0/24 | 0/13 | 0/35 | 0/11 | 0/24 | 0/13 | 0/36 | 0/12 |
| SuperinfectionInfections and infestations | 0/25 | 1/12 | 1/33 | 1/8 | 0/24 | 0/13 | 0/35 | 0/11 | 0/24 | 0/13 | 0/36 | 0/12 |
| Age, Customized(Participants) | AIN457 300 mg Q4W - TP 1 - CLP Cohort | Placebo - TP 1 - CLP Cohort | AIN457 300 mg Q4W - TP 1 - MLP Cohort | Placebo - TP 1 - MLP Cohort | AIN457 300 mg Q4W - TP 1 - LPP Cohort | Placebo - TP 1 - LPP Cohort | Total |
|---|---|---|---|---|---|---|---|
| 18 to <65 years | 22 | 9 | 14 | 8 | 19 | 12 | 84 |
| > or = 65 years | 3 | 3 | 10 | 5 | 5 | 1 | 27 |
| Sex: Female, Male(Participants) | AIN457 300 mg Q4W - TP 1 - CLP Cohort | Placebo - TP 1 - CLP Cohort | AIN457 300 mg Q4W - TP 1 - MLP Cohort | Placebo - TP 1 - MLP Cohort | AIN457 300 mg Q4W - TP 1 - LPP Cohort | Placebo - TP 1 - LPP Cohort | Total |
|---|---|---|---|---|---|---|---|
| Female | 15 | 8 | 14 | 12 | 20 | 10 | 79 |
| Male | 10 | 4 | 10 | 1 | 4 | 3 | 32 |
| Race/Ethnicity, Customized(Participants) | AIN457 300 mg Q4W - TP 1 - CLP Cohort | Placebo - TP 1 - CLP Cohort | AIN457 300 mg Q4W - TP 1 - MLP Cohort | Placebo - TP 1 - MLP Cohort | AIN457 300 mg Q4W - TP 1 - LPP Cohort | Placebo - TP 1 - LPP Cohort | Total |
|---|---|---|---|---|---|---|---|
| Asian (Indian) | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Black or African American | 6 | 4 | 2 | 1 | 1 | 0 | 14 |
| White | 19 | 8 | 19 | 12 | 23 | 13 | 94 |
| White, American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Baseline of Investigator's Global Assessment (IGA)(Participants) | AIN457 300 mg Q4W - TP 1 - CLP Cohort | Placebo - TP 1 - CLP Cohort | AIN457 300 mg Q4W - TP 1 - MLP Cohort | Placebo - TP 1 - MLP Cohort | AIN457 300 mg Q4W - TP 1 - LPP Cohort | Placebo - TP 1 - LPP Cohort | Total |
|---|---|---|---|---|---|---|---|
| 0=Clear | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1=Minimal | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| 2=Mild | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3=Moderate | 16 | 9 | 22 | 8 | 17 | 10 | 82 |
| 4=Severe | 8 | 3 | 2 | 5 | 7 | 3 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2020 to primary completion in Nov 2021, 15 months.
Results were first posted in Aug 2023, 1 year 9 months after primary completion. A results delay was requested in Jan 2022.
Of 16 phase 2 interventional studies under Lichen Planus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 15 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab